AMRX logo

AMNEAL PHARMACEUTICALS INC

AMRXNASDAQ
πŸ† #1068 by market capEarnings Oct 28US Equity
$17.10β–Ό $0.75 (βˆ’4.36%)
Market closed Β· at close
1hβ€”
24hβ–Ό 4.4%
7dβ–Ό 7.3%
14dβ–Ό 10.5%
30dβ–Ό 0.6%
1yβ–² 89.8%
🏦Market Cap
$5.46B
Small Cap
πŸ“ˆRevenue Growth (YoY)
+7.6%
Slowing
πŸ“ŠGross Margin
38.7%
Healthy
πŸ’΅FCF Margin
7.8%
Moderate
βš–οΈP/S Ratio
1.9x
Cheap
Otter Score
61
Fair

Trading Snapshot

Day Range
$17.03 – $17.25
52-Week Range
$8.21 – $19.26
Volume
$2.24B
Avg Volume
$2.37B
Shares Outstanding
319.3M
Next Earnings
Sep 7, 2026

Fundamentals Snapshot

Annual Revenue
$3.02B
Last Q Revenue
$796M
P/E Ratio
46.8
P/S Ratio
1.9x
EPS (TTM)
$0.37
Dividend Yield
β€”

Why Investors Own AMRX

  • βœ“High-growth profile β€” revenue up +5.5% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 51% gross margin and 13% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$3.02Bβ–² +6.5% YoY
Gross Margin (TTM)
50.5%β–² +4.3% YoY
Operating Income (TTM)
$1.10Bβ–² +6.5% YoY
Free Cash Flow (TTM)
$405Mβ–² +6.5% YoY

About AMNEAL PHARMACEUTICALS INC

Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
61/100

Analyst Price Target

β“˜
Average Target
$20.46
β–² +19.6% Upside
High Target$25.36
Low Target$17.30
Based on 16 analysts

Latest News & Updates